Behavioural and neurochemical comparison of chronic intermittent cathinone, mephedrone and MDMA administration to the rat

European Neuropsychopharmacology

Volumn 23, Issue 9, 2013, Pages 1085-1095

  Shortall, Sinead E ^a   Macerola, Alice E ^a   Swaby, Rabbi T R ^a   Jayson, Rebecca ^a   Korsah, Chantal ^a   Pillidge, Katharine E ^a   Wigmore, Peter M ^a   Ebling, Francis J P ^a   Richard Green, A ^a   Fone, Kevin C F ^a   King, Madeleine V ^a  

^a UNIVERSITY OF NOTTINGHAM   (United Kingdom)

Author keywords

5 HT; Cathinone; Dopamine; Locomotion; MDMA; Mephedrone

Indexed keywords

3,4 DIHYDROXYPHENYLACETIC ACID; 3,4 METHYLENEDIOXYMETHAMPHETAMINE; 4' METHYLMETHCATHINONE; 5 HYDROXYINDOLEACETIC ACID; CATHINONE; SEROTONIN;

ANIMAL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BEHAVIOR; BRAIN LEVEL; CHEMICAL ANALYSIS; CONDITIONING; CONTROLLED STUDY; CORPUS STRIATUM; DOPAMINE METABOLISM; DRUG EFFECT; EMOTION; FREEZING; FRONTAL CORTEX; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HIPPOCAMPUS; HYPERACTIVITY; LOCOMOTION; MALE; METABOLITE; NEUROCHEMISTRY; NEUROTOXICITY; NONHUMAN; PERCEPTIVE DISCRIMINATION; PREPULSE INHIBITION; PRIORITY JOURNAL; RAT; SEROTONIN METABOLISM; STARTLE REFLEX;

5-HT; CATHINONE; DOPAMINE; LOCOMOTION; MDMA; MEPHEDRONE;

ALKALOIDS; ANIMALS; BRAIN; CONDITIONING (PSYCHOLOGY); DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; MALE; METHAMPHETAMINE; MOTOR ACTIVITY; N-METHYL-3,4-METHYLENEDIOXYAMPHETAMINE; RANDOM ALLOCATION; RATS;

EID: 84884206647     PISSN: 0924977X     EISSN: 18737862     Source Type: Journal    
DOI: 10.1016/j.euroneuro.2012.09.005     Document Type: Article

References (50)

1. Aberg M., Wade D., Wall E., Izenwasser S. Effect of MDMA (ecstasy) on activity and cocaine conditioned place preference in adult and adolescent rats. Neurotoxicol. Teratol. 2007, 29:37-46.
2. ACMD, 2010. Consideration of the Cathinones. Home Office.
3. Armstrong B.D., Noguchi K.K. The neurotoxic effects of 3,4-methylenedioxymethamphetamine (MDMA) and methamphetamine on serotonin, dopamine, and GABA-ergic terminals: an in-vitro autoradiographic study in rats. Neurotoxicology 2004, 25:905-914.
4. Banjaw M.Y., Fendt M., Schmidt W.J. Clozapine attenuates the locomotor sensitization and the prepulse inhibition deficit induced by a repeated oral administration of Catha edulis extract and cathinone in rats. Behav. Brain. Res. 2005, 160:365-373.
5. Baumann M.H., Ayestas M.A., Partilla J.S., Sink J.R., Shulgin A.T., Daley P.F., Brandt S.D., Rothman R.B., Ruoho A.E., Cozzi N.V. The designer methcathinone analogs, mephedrone and methylone, are substrates for monoamine transporters in brain tissue. Neuropsychopharmacology 2012, 37:1192-1203.
6. Bolla K.I., McCann U.D., Ricaurte G.A. Memory impairment in abstinent MDMA ("Ecstasy") users. Neurology 1998, 51:1532-1537.
7. Brunt T.M., Poortman A., Niesink R.J.M., van den Brink W. Instability of the ecstasy market and a new kid on the block: mephedrone. J. Psychopharmacol. 2011, 25:1543-1547.
8. Bull E.J., Hutson P.H., Fone K.C. Reduced social interaction following 3,4-methylenedioxymethamphetamine is not associated with enhanced 5-HT2C receptor responsivity. Neuropharmacology 2003, 44:439-448.
9. Callaway C.W., Wing L.L., Geyer M.A. Serotonin release contributes to the locomotor stimulant effects of 3,4-methylenedioxymethamphetamine in rats. J. Pharmacol. Exp. Ther. 1990, 254:456-464.
10. Cappell H., Webster C.D., Ginsberg R. Amphetamine and conditioned anxiety. Brit. J. Pharmacol. 1972, 45:525-531.
11. Carvalho M., Carmo H., Costa V.M., Capela J.P., Pontes H., Remiao F., Carvalho F., Bastos Mde L. Toxicity of amphetamines: an update. Arch. Toxicol. 2012, 86:1167-1231.
12. Clemens K.J., Cornish J.L., Hunt G.E., McGregor L.S. Repeated weekly exposure to MDMA, methamphetamine or their combination: long-term behavioural and neurochemical effects in rats. Drug Alcohol Depen. 2007, 86:183-190.
13. Dargan P.I., Sedefov R., Gallegos A., Wood D.M. The pharmacology and toxicology of the synthetic cathinone mephedrone (4-methylmethcathinone). Drug Test. Anal. 2011, 3:454-463.
14. EMCDDA, 2011. Report on the Risk Assessment of Mephedrone in the Framework of the Council Decision on New Psychoactive Substances. The Publications Office of the European Union.
15. Fanselow M.S. Contextual fear, gestalt memories, and the hippocampus. Behav. Brain Res. 2000, 110:73-81.
16. Feyissa A.M., Kelly J.P. A review of the neuropharmacological properties of khat. Prog. Neuropsychopharmacol. Biol. Psychiatry 2008, 32:1147-1166.
17. Freeman T.P., Morgan C.J., Vaughn-Jones J., Hussain N., Karimi K., Curran H.V. Cognitive and subjective effects of mephedrone and factors influencing use of a 'new legal high'. Addiction 2012, 107:792-800.
18. Green A.R., King M.V., Shortall S.E., Fone K.C.F. Lost in translation: preclinical studies on 3,4-methylenedioxymethamphetamine provide information on mechanisms of action, but do not allow accurate prediction of adverse events in humans. Br. J. Pharmacol. 2012, 166:1523-1536.
19. Green A.R., Mechan A.O., Elliott J.M., O'Shea E., Colado M.I. The pharmacology and clinical pharmacology of 3,4-methylenedioxymethamphetamine (MDMA, "ecstasy"). Pharmacol. Rev. 2003, 55:463-508.
20. Hadlock G.C., Webb K.M., McFadden L.M., Chu P.W., Ellis J.D., Allen S.C., Andrenyak D.M., Vieira-Brock P.L., German C.L., Conrad K.M., Hoonakker A.J., Gibb J.W., Wilkins D.G., Hanson G.R., Fleckenstein A.E. 4-methylmethcathinone (mephedrone): neuropharmacological effects of a designer stimulant of abuse. J. Pharmacol. Exp. Ther. 2011, 339:530-536.
21. Hotchkiss A.J., Gibb J.W. Long-term effects of multiple doses of methamphetamine on tryptophan hydroxylase and tyrosine hydroxylase activity in rat brain. J. Pharmacol. Exp. Ther. 1980, 214:257-262.
22. Jones C.A., Brown A.M., Auer D.P., Fone K.C.F. The mGluR2/3 agonist LY379268 reverses post-weaning social isolation-induced recognition memory deficits in the rat. Psychopharmacology 2011, 214:269-283.
23. Kalivas P.W., Sorg B.A., Hooks M.S. The pharmacology and neural circuitry of sensitization to psychostimulants. Behav. Pharmacol. 1993, 4:315-334.
24. Kalix P. The amphetamine-like releasing effect of the alkaloid (-)cathinone on rat nucleus accumbens and rabbit caudate nucleus. Prog. Neuropsychopharmacol. Biol. Psychiatry 1982, 6:43-49.
25. Kehr J., Ichinose F., Yoshitake S., Goiny M., Sievertsson T., Nyberg F., Yoshitake T. Mephedrone, compared with MDMA (ecstasy) and amphetamine, rapidly increases both dopamine and 5-HT levels in nucleus accumbens of awake rats. Br. J. Pharmacol. 2011, 164:1949-1958.
26. Kelly J.P. Cathinone derivatives: a review of their chemistry, pharmacology and toxicology. Drug Test. Anal. 2011, 3:439-453.
27. King M.V., Sleight A.J., Woolley M.L., Topham I.A., Marsden C.A., Fone K.C. 5-HT6 receptor antagonists reverse delay-dependent deficits in novel object discrimination by enhancing consolidation: an effect sensitive to NMDA receptor antagonism. Neuropharmacology 2004, 47:195-204.
28. King M.V., Spicer C.H., Sleight A.J., Marsden C.A., Fone K.C. Impact of regional 5-HT depletion on the cognitive enhancing effects of a typical 5-ht(6) receptor antagonist, Ro 04-6790, in the novel object discrimination task. Psychopharmacology (Berlin) 2009, 202:111-123.
29. Lisek, R., Xu, W., Yuvasheva, E., Chiu, Y.T., Reitz, A.B., Liu-Chen, L.Y., Rawls, S.M. Mephedrone ('bath salt') elicits conditioned place preference and dopamine-sensitive motor activation. Drug Alcohol Depend., accepted for publication. http://dx.doi.org/10.1016/j.drugalcdep.2012.04.021.
30. Martinez-Clemente J., Escubedo E., Pubill D., Camarasa J. Interaction of mephedrone with dopamine and serotonin targets in rats. Eur. Neuropsychopharmacol. 2011, 22:231-236.
31. Montgomery C., Fisk J.E., Newcombe R. The nature of ecstasy-group related deficits in associative learning. Psychopharmacology (Berlin) 2005, 180:141-149.
32. Motbey C.P., Hunt G.E., Bowen M.T., Artiss S., McGregor I.S. Mephedrone (4-methylmethcathinone, 'meow'): acute behavioural effects and distribution of Fos expression in adolescent rats. Addict. Biol. 2012, 17:409-422.
33. O'Shea E., Escobedo I., Orio L., Sanchez V., Navarro M., Green A.R., Colado M.I. Elevation of ambient room temperature has differential effects on MDMA-induced 5-HT and dopamine release in striatum and nucleus accumbens of rats. Neuropsychopharmacology 2005, 30:1312-1323.
34. O'Shea E., Granados R., Esteban B., Colado M.I., Green A.R. The relationship between the degree of neurodegeneration of rat brain 5-HT nerve terminals and the dose and frequency of administration of MDMA ('ecstasy'). Neuropharmacology 1998, 37:919-926.
35. Parrott A.C., Lees A., Garnham N.J., Jones M., Wesnes K. Cognitive performance in recreational users of MDMA of 'ecstasy': evidence for memory deficits. J. Psychopharmacol. 1998, 12:79-83.
36. Pehek E.A., Schechter M.D., Yamamoto B.K. Effects of cathinone and amphetamine on the neurochemistry of dopamine in vivo. Neuropharmacology 1990, 29:1171-1176.
37. Phillips R.G., Ledoux J.E. Differential contribution of amygdala and hippocampus to cued and contextual fear conditioning. Behav. Neurosci. 1992, 106:274-285.
38. Piper B.J., Meyer J.S. Memory deficit and reduced anxiety in young adult rats given repeated intermittent MDMA treatment during the periadolescent period. Pharmacol. Biochem. Behav. 2004, 79:723-731.
39. Robinson T.E., Becker J.B. Behavioral sensitization is accompanied by an enhancement in amphetamine-stimulated dopamine release from striatal tissue in vitro. Eur. J. Pharmacol. 1982, 85:253-254.
40. Robinson T.E., Becker J.B. Enduring changes in brain and behavior produced by chronic amphetamine administration: a review and evaluation of animal models of amphetamine psychosis. Brain Res. 1986, 396:157-198.
41. Rodsiri R., Spicer C., Green A.R., Marsden C.A., Fone K.C. Acute concomitant effects of MDMA binge dosing on extracellular 5-HT, locomotion and body temperature and the long-term effect on novel object discrimination in rats. Psychopharmacology (Berlin) 2011, 213:365-376.
42. Schifano F., Albanese A., Fergus S., Stair J.L., Deluca P., Corazza O., Davey Z., Corkery J., Siemann H., Scherbaum N., Farre M., Torrens M., Demetrovics Z., Ghodse A.H. Mephedrone (4-methylmethcathinone; 'meow meow'): chemical, pharmacological and clinical issues. Psychopharmacology (Berlin) 2011, 214:593-602.
43. Shortall, S.E., Green, A.R., Swift, K.M., Fone, K.C.F., King, M.V., Differential effects of cathinone compounds and MDMA on body temperature in the rat, and pharmacological characterisation of mephedrone-induced hypothermia. Br. J. Pharmacol. Accepted for publication.
44. Van Hout M.C., Bingham T. "A Costly Turn On": patterns of use and perceived consequences of mephedrone based head shop products amongst Irish injectors. Int. J. Drug Policy 2012, 23:188-197.
45. Vollenweider F.X., Remensberger S., Hell D., Geyer M.A. Opposite effects of 3,4-methylenedioxymethamphetamine (MDMA) on sensorimotor gating in rats versus healthy humans. Psychopharmacology (Berlin) 1999, 143:365-372.
46. Watson D.J.G., Loiseau F., Marsden C.A., Millan M.J., Fone K.C.F. Selective blockade of dopamine D3 vs D2 receptors enhances novel object recognition in rats: role of the prefrontal cortex. J. Psychopharmacol. 2011, 25:A26.
47. Winstock A., Mitcheson L., Ramsey J., Davies S., Puchnarewicz M., Marsden J. Mephedrone: use, subjective effects and health risks. Addiction 2011, 106:1991-1996.
48. Winstock A.R., Mitcheson L.R., Deluca P., Davey Z., Corazza O., Schifano F. Mephedrone, new kid for the chop?. Addiction 2011, 106:154-161.
49. Wood D.M., Measham F., Dargan P.I. 'Our favourite drug': prevalence of use and preference for mephedrone in the London night-time economy 1 year after control. J. Subst. Use 2012, 17:91-97.
50. Wright, M.J., Jr., Vandewate, S.A., Angrish, D., Dickerson, T.J., Taffe, M.A. Mephedrone (4-methylmethcathinone, 4MMC) and d-methamphetamine improve visuo-spatial associative memory, but not spatial working memory, in rhesus macaques. Br. J. Pharmacol., accepted for publication. http://dx.doi.org/10.1111/j.1476-5381.2012.02091.x.